Table S1 Details of ACT

| Chemotherapy agent | n (%)  | Duration (cycles) |
|---------------------|--------|-------------------|
| FOLFOX              | 24 (25.2%) | 3.9 ± 1.8        |
| XELOX               | 45 (47.4%) | 3.4 ± 0.8        |
| FOLFIRI             | 7 (7.4%) | 3.4 ± 0.7        |
| Capecitabine        | 19 (20.0%) | 4.2 ± 0.9        |

ACT, adjuvant chemotherapy; FOLFIRI, folinic acid, fluorouracil, and irinotecan; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; XELOX, capecitabine and oxaliplatin

Table S2 Patterns of Recurrence

|                      | ACT (n=95) | Non-ACT (n=43) | P    |
|----------------------|------------|----------------|------|
| Local recurrence     | 4          | 2              |      |
| Distant metastasis   |            |                |      |
| Bone                 | 2          | 1              |      |
| Peritoneal           | 3          | 1              |      |
| Central pevis        | 3          | 0              |      |
| Liver                | 4          | 1              |      |
| Lung                 | 4          | 1              |      |
| Total (%)            | 20 (21.0)  | 6 (14.0)       | 0.320|

ACT, adjuvant chemotherapy
**Figure S1:** Determination of cut-off values of age in the entire cohort. The optimal cut-off values in the left panels are shown in histograms of the whole cohort (middle panels), and Kaplan-Meier plots are displayed in the right panels. The optimal cut-off value of age is 64 years.

**Figure S2:** Kaplan-Meier curves for disease-free survival rates based on the ypStage (A) and age (B).